z-logo
open-access-imgOpen Access
Relation between blaTEM, blaSHV and blaCTX-M genes and acute urinary tract infections
Author(s) -
Sima Sadat Seyedjavadi,
Mehdi Goudarzi,
Fattaneh Sabzehali
Publication year - 2016
Publication title -
journal of acute disease
Language(s) - English
Resource type - Journals
eISSN - 2589-5516
pISSN - 2221-6189
DOI - 10.1016/j.joad.2015.07.007
Subject(s) - amikacin , imipenem , microbiology and biotechnology , antibiotics , agar diffusion test , medicine , escherichia coli , urinary system , antibiotic resistance , biology , gene , genetics
ObjectiveTo survey the frequency of blaTEM, blaSHV and blaCTX-M genotypes in extended-spectrum β-lactamase (ESBL)-producing Escherichia coli (E. coli) isolated from hospitalized patients with urinary tract infection and the determination of their antibiotic resistance patterns.MethodsDuring 11-month study, 100 ESBL-producing E. coli were collected from 330 patients who met the definition of urinary tract infection. The phenotypic identification of ESBL was confirmed by double disk synergy test and combined disk diffusion test. In vitro, susceptibility to ESBL isolates than 14 antimicrobial agents was performed by Kirby-Bauer disk diffusion method. The frequency of blaTEM, blaSHV and blaCTX-M ESBL-producing E. coli was assessed by PCR method.ResultsThe frequency of ESBL-producing E. coli was 40.8%. In vitro, susceptibility to ESBL-producing E. coli showed that the majority of isolates were highly susceptible to amikacin (74%) and imipenem (91%). The rates of resistance to other antibiotics varied from 33% to 96%. Through 100 tested isolates, the prevalence of blaTEM, blaSHV and blaCTX-M genes was determined to be 67%, 45% and 74% respectively. In comparison with other bla genes, the frequency of blaCTX-M was strikingly high.ConclusionsDue to the increase of E. coli with multiple ESBL genes, continuous surveillance in order to use appropriate antibiotics and the control of infections is necessary

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here